Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy

Abstract

Background. A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer.

Investigations. Urinalysis, CT, microscopic examination of tumor, immunohistochemical analysis of tumor, hemoglobin electrophoresis, molecular cytogenetic analysis, gene sequencing.

Diagnosis. Renal medullary-like carcinoma in an adult without sickle cell trait, sickle cell disease or other hemoglobinopathies.

Management. The patient underwent laparoscopic nephrectomy to remove the tumor and received adjuvant sorafenib (400 mg per day) as part of the E2805 ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial. Metastatic recurrence of the tumor occurred 9 months after nephrectomy, for which the patient underwent tumor debulking and retroperitoneal lymph node dissection, followed by chemotherapy consisting of gemcitabine (2,000 mg/m2) and doxorubicin (50 mg/m2), both given on day 1 of a 14-day cycle. After six cycles of drug treatment, the patient had achieved a partial response. The patient was managed by active surveillance for 4 months, when he developed further symptoms and disease progression was detected. Third-line systemic therapy in the form of 21-day cycles of cisplatin (80 mg/m2 on day 1) and etoposide (100 mg/m2 on days 1–3) has recently been initiated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: CT of the abdomen.
Figure 2: Gross appearance of left renal mass.
Figure 3: Microscopic analysis of left kidney mass.

References

  1. Cheng, J. X. et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod. Path. 21, 647–652 (2008).

    Article  CAS  Google Scholar 

  2. Davis, C. J. Jr, Mostofi, F. K. & Sesterhenn, I. A. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am. J. Surg. Pathol. 19, 1–11 (1995).

    Article  PubMed  Google Scholar 

  3. Swartz, M. A. et al. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology 60, 1083–1089 (2002).

    Article  PubMed  Google Scholar 

  4. Hakimi, A. A. et al. Renal medullary carcinoma: the Bronx experience. Urology 70, 878–882 (2007).

    Article  PubMed  Google Scholar 

  5. Wang, W. et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 15, 5370–5382 (1996).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Biegel, J. A. Cytogenetics and molecular genetics of childhood brain tumors. Neuro. Oncol. 1, 139–151 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sigauke, E. et al. Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod. Pathol. 19, 717–725 (2006).

    Article  CAS  PubMed  Google Scholar 

  8. Biegel, J. A., Rorke, L. B., Packer, R. J. & Emanuel, B. S. Monosomy 22 in rhabdoid or atypical tumors of the brain. J. Neurosurg. 73, 710–714 (1990).

    Article  CAS  PubMed  Google Scholar 

  9. Schofield, D. E., Beckwith, J. B. & Sklar, J. Loss of heterozygosity at chromosome regions 22q11–12 and 11p15.5 in renal rhabdoid tumors. Genes Chromosomes Cancer 15, 10–17 (1996).

    Article  CAS  PubMed  Google Scholar 

  10. Biegel, J. A. et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59, 74–79 (1999).

    CAS  PubMed  Google Scholar 

  11. Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203–206 (1998).

    Article  CAS  PubMed  Google Scholar 

  12. Rickert, C. H. & Paulus, W. Chromosomal imbalances detected by comparative genomic hybridisation in atypical teratoid/rhabdoid tumours. Childs Nerv. Syst. 20, 221–224 (2004).

    Article  PubMed  Google Scholar 

  13. Karnes, P. S. et al. Cytogenetic analysis of 39 pediatric central nervous system tumors. Cancer Genet. Cytogenet. 59, 12–19 (1992).

    Article  CAS  PubMed  Google Scholar 

  14. Lopez-Gines, C. et al. Complex rearrangement of chromosomes 6 and 11 as the sole anomaly in atypical teratoid/rhabdoid tumors of the central nervous system. Cancer Genet. Cytogenet. 122, 149–152 (2000).

    Article  CAS  PubMed  Google Scholar 

  15. Proust, F. et al. Simultaneous presentation of atypical teratoid/rhabdoid tumor in siblings. J. Neurooncol. 43, 63–70 (1999).

    Article  CAS  PubMed  Google Scholar 

  16. Stahlschmidt, J., Cullinane, C., Roberts, P. & Picton, S. V. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement. Med. Pediatr. Oncol. 33, 551–557 (1999).

    Article  CAS  PubMed  Google Scholar 

  17. Yan, B. C., Mackinnon, A. C. & Al-Ahmadie, H. A. Recent developments in the pathology of renal tumors: morphology and molecular characteristics of select entities. Arch. Pathol. Lab. Med. 133, 1026–1032 (2009).

    CAS  PubMed  Google Scholar 

  18. Roberts, C. W., Leroux, M. M., Fleming, M. D. & Orkin, S. H. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2, 415–425 (2002).

    Article  CAS  PubMed  Google Scholar 

  19. Biegel, J. A. et al. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res. 62, 323–328 (2002).

    CAS  PubMed  Google Scholar 

  20. Motzer, R. J. et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376–2381 (2002).

    Article  PubMed  Google Scholar 

  21. Noguera-Irizarry, W. G., Hibshoosh, H. & Papadopoulos, K. P. Renal medullary carcinoma: case report and review of the literature. Am. J. Clin. Oncol. 26, 489–492 (2003).

    Article  PubMed  Google Scholar 

  22. Yang, X. J. et al. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer 100, 976–985 (2004).

    Article  PubMed  Google Scholar 

  23. Dodd, P. M. et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J. Clin. Oncol. 18, 840–846 (2000).

    Article  CAS  PubMed  Google Scholar 

  24. Galsky, M. D. et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109, 549–555 (2007).

    Article  CAS  PubMed  Google Scholar 

  25. Milowsky, M. I., Rosmarin, A., Tickoo, S. K., Papanicolaou, N. & Nanus, D. M. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 94, 111–116 (2002).

    Article  PubMed  Google Scholar 

  26. Kalyanpur, A. et al. Renal medulla carcinoma in a white adolescent. AJR Am. J. Roentgenol. 169, 1037–1038 (1997).

    Article  CAS  PubMed  Google Scholar 

  27. Prasad, S. R. et al. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 26, 1795–1806 (2006).

    Article  PubMed  Google Scholar 

  28. Choyke, P. L., Glenn, G. M., Walther, M. M., Zbar, B. & Linehan, W. M. Hereditary renal cancers. Radiology 226, 33–46 (2003).

    Article  PubMed  Google Scholar 

  29. Linehan, W. M., Walther, M. M. & Zbar, B. The genetic basis of cancer of the kidney. J. Urol. 170, 2163–2172 (2003).

    Article  CAS  PubMed  Google Scholar 

  30. Hoot, A. C., Russo, P., Judkins, A. R., Perlman, E. J. & Biegel, J. A. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am. J. Surg. Pathol. 28, 1485–1491 (2004).

    Article  PubMed  Google Scholar 

  31. Modena, P. et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 65, 4012–4019 (2005).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hikmat Al-Ahmadie.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Donnell, P., Jensen, A., Posadas, E. et al. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol 7, 110–114 (2010). https://doi.org/10.1038/nrurol.2009.255

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2009.255

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer